ArticleTropical medicine & international health : TM & IH2026
Breakthrough Tuberculosis in a Large Cohort of People Living With HIV on Preventive Treatment.
Article in Tropical medicine & international health : TM & IH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis is a leading infectious cause of death globally and the main cause among those with HIV. TB preventive treatment (TPT) is key for preventing TB in people with HIV (PWH). Healthcare workers often worry about adverse effects of TPT regimens, including breakthrough TB-active TB during treatment. The burden of breakthrough TB remains largely unknown. This study aimed to determine the incidence and factors associated with breakthrough TB in PWH receiving HIV care.
methodsWe analysed the nationwide electronic patient management system (EPMS) for HIV care and TB registers in Namibia, following PWH registered for HIV care to determine TB incidence before, during and after TPT and applying logistic regression to determine factors associated with breakthrough TB.
resultsOf 334,606 PWH reviewed, 46,199 developed TB before, during, or after receiving TPT while being followed up for HIV care. PWH were followed for 114,667 patient-years (PYs) while receiving TPT, with breakthrough TB incidence of 1.40 per 100 PYs (95% CI: 1.33-1.47). The 1790 true breakthrough cases had a median age of 37 (IQR 30-45). Median time to breakthrough TB was 2.5 months. Only 43 (2.4%) cases were drug-resistant TB. In a logistic regression model comparing breakthrough versus non-breakthrough TB cases, receiving ART increased breakthrough TB risk (aOR = 2.88; 95% CI: 1.07-7.78). The 3 month isoniazid-rifapentine TPT regimen showed lower risk (aOR = 0.46; 95% CI: 0.36-0.63) than the 6 month isoniazid regimen, while 9H increased risk (aOR = 1.44; 95% CI: 1.18-2.52) but incidence rates were comparable between the regimens.
conclusionThe incidence of breakthrough TB was low at 1.4 per 100 PYs of TPT provision but indicating a need for improved screening of PWH before TPT. The incidence rate of TB among PWH during and after the shorter TPT regimen (3HP) is comparable to that of the 6H and 9H regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.